|
|
|
市場調査レポート
多様な疾病の治療に利用される酵素阻害薬の市場
Enzyme Inhibitors with Broad Therapeutic Applications
| 発行 |
BCC Research |
| 出版日 |
2006年06月 |
商品コード |
42184 |
| ページ情報 |
英文 165 pages 48 tables |
| 価格 |
|
|
Abstract
INTRODUCTION
The aim of this report is to provide a range of information-from detailed
market analyses through industry trends-to quantify and qualify the market for
therapeutic enzyme inhibitors with large markets and/or broad therapeutic
applications.
This report offers a broad detailed overview of enzyme inhibitors currently on
the market and those in late-stage clinical trials. The information and
analysis presented in this report are important assets in decision-making for
managers involved in business development, marketing, market research, product
development, mergers and acquisitions, licensing, business management,
investment banking and deal creation, and to consultants to the pharmaceutical
and biotechnology industry. The study provides a comprehensive analysis of the
current markets for enzyme inhibiting drugs and, in particular, the market
potential of promising drugs and technologies under development.
SCOPE OF STUDY
This report contains:
- The major current and emerging therapeutic markets for enzyme inhibitors
used in human therapeutics,
- A discussion of the biochemistry for enzyme inhibitors and classes of
enzyme inhibiting products with broad current or potential therapeutic
applications or large markets,
- A synopsis of more than 100 enzyme inhibitors, including those currently
marketed and those in Phase II or later development,
- An overview of the leading indications for available and emerging enzyme
inhibitors. These include selected indications for asthma and chronic
obstructive pulmonary disease (COPD), cardiovascular diseases, erectile
dysfunction, gastrointestinal disorders, hepatitis B virus infection,
hepatitis C virus infection, herpesvirus infections, human immunodeficiency
virus (HIV)/acquired immune deficiency syndrome (AIDS) and rheumatoid
arthritis and related inflammatory diseases,
- Forecasts for the global market, through 2011,
- Company Profiles emphasizing companies that lead the pharmaceutical and
biotechnology industry in the research and development of enzyme-inhibiting
drugs.
METHODOLOGY
The base year for this study is 2005. Figures are based on revenue figures at
the manufacturers' level and are projected at 2005 dollar value; that is,
inflation is not computed into the projection figures.
Information to prepare this study was derived from information obtained from
product managers, marketing strategists, research executives and others at
leading pharmaceutical and biotechnology companies that compete in the market
for enzyme inhibitors or which have products in development for this market.
INFORMATION SOURCES
The information and analyses presented in this report are based on an
extensive survey of the biotechnology and pharmaceutical industries as well as
a detailed examination of published literature and reports obtained from
regulatory authorities, medical research institutions, pharmaceutical trade
associations and national and world health organizations. Key information from
the business literature was used as to obtain expert opinion on commercial
potential and market sizes from industry professionals.
ABOUT THE AUTHOR
Lynn Gray has been a research analyst in biotechnology and life sciences since
1989 and with BCC since 1996. During that time, she has authored more than 20
research reports in the biomedical field for BCC Research.
Table of Contents
- INTRODUCTION
- OBJECTIVES AND GOALS OF THE STUDY
- CONTRIBUTIONS OF THE STUDY AND FOR WHOM
- SCOPE AND FORMAT
- METHODOLOGY
- INFORMATION SOURCES
- ABOUT THE AUTHOR
- RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS
- BCC ONLINE SERVICES
- DISCLAIMER
- EXECUTIVE SUMMARY
- Summary Table:
- GLOBAL FORECAST OF ENZYME INHIBITOR CLASS REVENUES, THROUGH 2011 ($
MILLIONS)
- Summary Figure:
- PERCENTAGE OF REVENUES BY ENZYME INHIBITOR CLASS, IN 2005 AND 2011 (%)
- OVERVIEW
- BACKGROUND
- ENZYMES
- Figure 1 HOW AN ENZYME COMBINES TWO CHEMICALS
- THE FUNCTION OF ENZYME INHIBITORS
- TYPES OF INHIBITORS
- Competitive, Noncompetitive, and Uncompetitive
- Figure 2 COMPETITIVE INHIBITION
- Figure 3 NONCOMPETITIVE INHIBITION
- Reversible and Irreversible
- Selective and Nonselective
- CLASSES OF ENZYME INHIBITORS
- Table 1 ENZYME INHIBITORS BY CLASS: DEFINITION AND EXAMPLES
- Table 1 (CONTINUED)
- CYCLOOXYGENASE INHIBITORS
- DNA POLYMERASE INHIBITORS
- INTEGRASE INHIBITORS
- PHOSPHODIESTERASE INHIBITORS
- PROTEASE INHIBITORS
- PROTON PUMP INHIBITORS (ATPASE INHIBITORS)
- TRANSCRIPTASE INHIBITORS
- HIV REVERSE TRANSCRIPTASE
- PRODUCTS
- COX-2 INHIBITORS
- COX-2 PRODUCTS ON THE MARKET
- Celebrex
- Mobic
- The Market for COX-2 Inhibitors
- Table 2 GLOBAL MARKET FORECAST FOR COX-2 INHIBITORS BY PRODUCT, THROUGH
2011 ($ MILLIONS)
- Table 3 U.S. MARKET FORECAST FOR COX-2 INHIBITORS BY PRODUCT, THROUGH
2011 ($ MILLIONS)
- PRODUCTS AWAITING FDA APPROVAL
- NEXT-GENERATION COX-2 INHIBITORS
- AFTER-EFFECTS OF THE WITHDRAWAL OF VIOXX AND BEXTRA
- After-Effects of the Withdrawal...(Continued)
- After-Effects of the Withdrawal...(Continued)
- Creating an Unwarranted Market?
- The FDA Takes a Hard Look at Direct-To-Consumer Advertising
- The Future of COX-2 Inhibitors
- The Future of COX-2 Inhibitors (Continued)
- The Effect of Insurance Company Reimbursement
- PHOSPHODIESTERASE INHIBITORS
- PDE1 INHIBITORS
- PDE3 INHIBITORS
- PDE3 Inhibitors in Phase II or Later Development
- PDE4 INHIBITORS
- PDE4 Inhibitors (Continued)
- The Market for PDE4 Inhibitors
- Table 4 GLOBAL MARKET FORECAST FOR PDE4 INHIBITORS BY PRODUCT, THROUGH
2011 ($ MILLIONS)
- Table 5 U.S. MARKET FORECAST FOR PDE4 INHIBITORS BY PRODUCT, THROUGH
2011 ($ MILLIONS)
- PRODUCT
- PDE4 Inhibitors in Phase II or Later Development
- Table 6 PDE4 INHIBITORS IN PHASE II OR LATER DEVELOPMENT
- Ariflo
- Awd12-281
- Daxas
- IC485
- Ono-6126
- Drawbacks of PDE4 Inhibitors Currently in Development
- PDE5 INHIBITORS
- Marketed Products
- Cialis
- Levitra
- Revatio
- Viagra
- Zydena
- The Market for PDE5 Inhibitors
- Table 7 GLOBAL MARKET FORECAST FOR PDE5 INHIBITORS BY PRODUCT, THROUGH
2011 ($ MILLIONS)
- Table 8 U.S. MARKET FORECAST FOR PDE5 INHIBITORS BY PRODUCT, THROUGH
2011 ($ MILLIONS)
- PDE5 Inhibitors in Phase II or Later Development
- Table 9 PDE5 INHIBITORS IN PHASE II OR LATER DEVELOPMENT
- NM 702
- TA-1790
- Tadalafil
- PDE7 INHIBITORS
- PDE10 INHIBITORS
- PROTON PUMP INHIBITORS
- ACIPHEX/PARIET
- NEXIUM
- PREVACID
- PRILOSEC/LOSEC
- PANTOZOL
- PROTONIX/ PROTIUM
- TAKEPRON
- ZEGERID
- GENERIC PROTON PUMP INHIBITORS
- COMPARISON OF PROTON PUMP INHIBITORS
- Table 10 BRANDED PRESCRIPTION PROTON PUMP INHIBITORS AND SUPPLIERS
- COST OF PROTON PUMP INHIBITORS
- THE MARKET FOR PROTON PUMP INHIBITORS
- Table 11 GLOBAL MARKET FORECAST FOR PRESCRIPTION, BRANDED PROTON PUMP
INHIBITORS BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 12 U.S. MARKET FOR PRESCRIPTION, BRANDED PROTON PUMP INHIBITORS BY
PRODUCT, THROUGH 2011 ($ MILLIONS)
- PRODUCT
- TRANSCRIPTASE INHIBITORS
- LACK OF INCENTIVE TO DEVELOP DRUGS TO TREAT HIV AND AIDS
- THE IMPACT OF THE AVAILABILITY OF ANTIRETROVIRAL THERAPY
- THE INTRODUCTION OF HAART
- Table 13 NUMBER OF DEATHS FROM AIDS IN THE U.S., 1988-2005
- THE FIRST GENERIC HIV/AIDS DRUG ENTERS THE U.S. MARKET
- EFFORTS TO REDUCE THE COST OF HIV DRUGS IN THE DEVELOPING WORLD
- Boehringer Ingelheim and GlaxoSmithKline Sign Agreements
- AIDS Healthcare Foundation Lawsuit
- Sub-Saharan Africa Generic Production Agreement
- Merck Reduces the Cost of Stocrin
- EFFORTS TO MAKE GENERIC HIV DRUGS AVAILABLE IN DEVELOPING COUNTRIES
- The World Trade Organization Steps In
- Generic AIDS Drug Combinations Approved by the FDA for Emergency
AIDS Relief Plan
- A Strategy to Gain a Foothold in the World Market
- Clinton Foundation Negotiates Lower Drug Prices for Poor Countries
- Other Struggles to Gain Access to Generic HIV Drugs
- "THE 3 BY 5 INITIATIVE"
- Main Plan Objectives
- Status at the End of 2005
- DRUG RESISTANCE IN HIV/AIDS
- Definition of Antiviral Drug Resistance
- How Resistance Develops
- Locations of Mutations
- Types of Resistance
- Current Status of Resistance
- 2003 CATCH Study
- Resistance among HIV Cases in Europe
- Table 14 RESISTANCE AMONG HIV-POSITIVE PATIENTS IN EUROPE AS DETERMINED
BY THE CATCH STUDY
- Conclusions
- Novel Drug Resistance Treatment Strategies
- Acute Infection and Early Disease Research Program
- Types of Drug Resistance Testing
- Genotypic and Phenotypic Testing
- Genotypic Testing
- Table 15 PROTEASE MUTATIONS
- Table 15 (CONTINUED)
- Table 16 REVERSE TRANSCRIPTASE MUTATIONS
- Phenotypic Testing
- Comparison of Genotypic Versus Phenotypic Testing
- Table 17 ADVANTAGES AND DISADVANTAGES OF GENOTYPIC VERSUS PHENOTYPIC
TESTING
- Reimbursement for HIV Drug Resistance Testing
- Guidelines for HIV Drug Resistance Testing
- The Special Case of Protease Inhibitors
- The Rationale for Genotypic Testing for HIV-I Drug Resistance
- Available HIV Drug Resistance Tests
- SALIVA TESTS APPROVED TO DETECT HIV
- COST OF HIV/AIDS TREATMENT
- Table 18 ESTIMATED ANNUAL COSTS FOR HAART IN U.S. AND SUB-SAHARAN AFRICA
- ABBOTT INCREASES THE COST OF NORVIR FIVE-FOLD
- Abbott Increases the Cost...(Continued)
- Table 19 COMPARISON OF AVERAGE ANNUAL COST OF BOOSTED* PROTEASE
INHIBITOR-BASED HIV TREATMENT REGIMENS BEFORE AND AFTER NORVIR PRICE
INCREASE ($)
- AVAILABLE PRODUCTS FOR THE TREATMENT OF HIV INFECTION AND AIDS
- Table 20 FDA-APPROVED DRUGS FOR THE TREATMENT OF HIV INFECTION/AIDS
- Table 20 (CONTINUED)
- THE MARKET FOR ENZYME-INHIBITING PRODUCTS TO TREAT HIV INFECTION AND
AIDS
- Table 21 GLOBAL MARKET FORECAST FOR ENZYME-INHIBITING HIV/AIDS
THERAPEUTICS, THROUGH 2011 ($ MILLIONS)
- Table 21 (CONTINUED)
- Table 22 GLOBAL MARKET FORECAST FOR ENZYME-INHIBITING HIV/AIDS
THERAPEUTICS BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Figure 4 MARKET SHARE OF ENZYME-INHIBITING HIV/AIDS DRUGS BY PRODUCT
CATEGORY, WORLDWIDE SALES: 2006 AND 2011 (%)
- THE U.S. MARKET FOR ENZYME-INHIBITING HIV/AIDS DRUGS
- Table 23 U.S. MARKET FORECAST FOR ENZYME-INHIBITING HIV/AIDS
THERAPEUTICS, THROUGH 2011 ($ MILLIONS)
- Figure 5 U.S. MARKET FORECAST FOR ENZYME-INHIBITING HIV/AIDS
THERAPEUTICS, 2004-2011 ($ MILLIONS)
- COMBINATION PRODUCTS EMERGE AS PREFERRED TREATMENT
- LEADING MARKETERS OF HIV/AIDS DRUGS
- Leaders in the Nucleoside Reverse Transcriptase Inhibitor Class
- CATEGORIES OF ENZYME-INHIBITING DRUGS AVAILABLE FOR THE TREATMENT OF
HIV/AIDS
- Nonnucleoside Reverse Transcriptase Inhibitors
- Nucleoside Reverse Transcriptase Inhibitors
- Nucleotide Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Side Effects of Marketed HIV Drugs
- Adverse Cardiovascular Events
- SELECTED TRANSCRIPTASE-INHIBITING DRUGS INTRODUCED TO THE U.S. MARKET
IN 2003, 2004 AND 2005
- Table 24 ENZYME INHIBITING PRODUCT INTRODUCTIONS FOR THE TREATMENT OF
HIV INFECTION, U.S., 2002-2005
- Nonnucleoside Reverse Transcriptase Inhibitors
- Nucleoside Reverse Transcriptase Inhibitors
- Emtriva
- Epizicom
- Truvada
- Nucleotide Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Aptivus
- Lexiva/Telzir
- Reyataz
- DOSING AND COMPLIANCE CHALLENGES
- Table 25 DAILY DOSAGE REQUIREMENTS FOR SELECTED HIV/AIDS THERAPIES
- Table 26 RELATIONSHIP BETWEEN COMPLIANCE AND DOSING FREQUENCY
- THE IDEAL TREATMENT REGIMEN
- THE NUMBER OF SALVAGE PATIENTS CONTINUES TO INCREASE
- ENZYME-INHIBITING DRUGS IN DEVELOPMENT FOR THE TREATMENT AND/OR
PREVENTION OF HIV INFECTION AND AIDS
- Table 27 ENZYME-INHIBITING PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR
THE TREATMENT AND/OR PREVENTION OF HIV INFECTION/AIDS
- Table 27 (CONTINUED)
- THE THREE MAIN ENZYME TARGETS FOR ANTIRETROVIRAL DRUGS
- Integrase
- Protease
- Protease Inhibitors in Phase II or Later Development
- Reverse Transcriptase
- Nonnucleoside Reverse Transcriptase Inhibitors In Phase II Or Later
Development
- Calanolide A
- Capravirine
- Etravirine
- MIV-150
- MIV-210
- TMC-278
- Nucleoside Reverse Transcriptase Inhibitors In Phase II Or Later
Development
- Alovudine
- Amdoxovir
- Dexelvucitabine
- Elvucitabine
- Racivir
- SPD754
- TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF OTHER VIRAL DISEASES
- Marketed Transcriptase Inhibitors For The Treatment Of Other Viral
Diseases
- Table 28 MARKETED NUCLEOSIDE ANALOG INHIBITORS FOR THE TREATMENT OF
OTHER VIRAL DISEASES
- Table 28 (CONTINUED)
- Nucleoside Analogs Introduced Between 2003 and 2005 for the Treatment
of Other Viral Diseases
- The Market for Nucleoside Analogs to Treat Other Viral Diseases
- Table 29 GLOBAL MARKET FORECAST FOR NUCLEOSIDE ANALOG-BASED DRUGS TO
TREAT OTHER VIRAL DISEASES, THROUGH 2011 ($ MILLIONS)
- Figure 6 GLOBAL MARKET FORECAST FOR NUCLEOSIDE ANALOG-BASED DRUGS TO
TREAT OTHER VIRAL DISEASES, 2004-2011 ($ MILLIONS)
- Nucleoside Analogs in Phase II Or Later Development for Other Viral
Diseases
- Hepatitis B Virus Infection
- Clevudine
- Elvucitabine
- MIV-210
- Pradefovir Mesylate
- Telbivudine
- Tenofovir Disoproxil Fumarate
- Valtorcitabine
- Hepatitis C Virus Infection
- GS1392
- JTK-003
- Valopicitabine
- Viramidine
- VX-950
- Herpesvirus Infections
- APPLICATIONS
- ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- ASTHMA
- CHRONIC OBSTRUCTIVE PULMONARY DISEASE
- THE ROLE OF CYTOKINES IN ASTHMA AND COPD
- THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT ASTHMA AND COPD
- Table 30 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
ASTHMA AND COPD, THROUGH 2011 ($ MILLIONS)
- Figure 7 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
ASTHMA AND COPD, 2004-2011 ($ MILLIONS)
- BENIGN PROSTATIC HYPERPLASIA
- CARDIOVASCULAR DISEASES
- CONGESTIVE HEART FAILURE
- Congestive Heart Failure (Continued)
- HYPERTENSION
- INTERMITTENT CLAUDICATION
- PULMONARY ARTERIAL HYPERTENSION
- THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT CARDIOVASCULAR
DISEASES
- Table 31 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
CARDIOVASCULAR DISEASES, THROUGH 2011 ($ MILLIONS)
- Figure 8 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
CARDIOVASCULAR DISEASES, 2004-2011 ($ MILLIONS)
- ERECTILE DYSFUNCTION
- THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT ERECTILE DYSFUNCTION
- Table 32 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
ERECTILE DYSFUNCTION, THROUGH 2011 ($ MILLIONS)
- Figure 9 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
ERECTILE DYSFUNCTION, 2004-2011 ($ MILLIONS)
- GASTROINTESTINAL DISEASES
- THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT GASTROINTESTINAL
DISORDERS
- Table 33 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
GASTROINTESTINAL DISORDERS, THROUGH 2011 ($ MILLIONS)
- Figure 10 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
GASTROINTESTINAL DISORDERS, 2004-2011 ($ MILLIONS)
- HEPATITIS B VIRUS INFECTION
- THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT HEPATITIS B INFECTION
- Table 34 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
HEPATITIS B INFECTION, THROUGH 2011 ($ MILLIONS)
- Figure 11 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
HEPATITIS B INFECTION, 2004-2011 ($ MILLIONS)
- HEPATITIS C VIRUS INFECTION
- THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT HEPATITIS C INFECTION
- Table 35 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
HEPATITIS C INFECTION, THROUGH 2011 ($ MILLIONS)
- HERPESVIRUS INFECTIONS
- CYTOMEGALOVIRUS
- HERPES SIMPLEX VIRUS
- HERPES ZOSTER VIRUS
- THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT HERPESVIRUS
INFECTIONS
- Table 36 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
HERPESVIRUS INFECTIONS, THROUGH 2011 ($ MILLIONS)
- HUMAN IMMUNODEFICIENCY VIRUS INFECTION AND ACQUIRED IMMUNE DEFICIENCY
SYNDROME
- HIV AND AIDS STATISTICS
- Number of HIV/Living with AIDS Cases in 2005 by Geographic Region
- Table 37 ESTIMATED NUMBER OF PERSONS INFECTED WITH HIV/LIVING WITH AIDS,
ADULTS AND CHILDREN, BY GEOGRAPHIC REGION, 2005
- Geographic Region 2005 Percentage of Global HIV Cases by Geographic
Region
- Table 38 PERCENTAGE OF GLOBAL HIV CASES BY GEOGRAPHIC REGION, 2005
- New HIV Cases in 2005 by Region
- Table 39 ESTIMATED NUMBER OF PEOPLE NEWLY INFECTED WITH HIV, ADULTS AND
CHILDREN, BY GEOGRAPHIC REGION, 2005
- 2005 AIDS Deaths by Region
- Table 40 ESTIMATED NUMBER OF DEATHS FROM AIDS, ADULTS AND CHILDREN, BY
GEOGRAPHIC REGION, 2005
- Estimated Number of HIV Cases by Country in 2002 and 2010
- Table 41 ESTIMATED NUMBER OF PEOPLE INFECTED WITH HIV IN SELECTED
COUNTRIES, 2002 AND 2010 (MILLION)
- HIV INFECTION AND AIDS CASES IN THE U.S.
- THE NEED FOR BETTER ACCESS TO TREATMENT
- Table 42 PERCENT OF PATIENTS RECEIVING ANTIRETROVIRAL TREATMENT FOR HIV
INFECTION BY GEOGRAPHIC REGION
- ENZYME INHIBITORS TO TREAT HIV/AIDS
- THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT HIV INFECTION AND AIDS
- Table 43 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT HIV
INFECTION AND AIDS, THROUGH 2011 ($ MILLIONS)
- Figure 12 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
HIV INFECTION AND AIDS, 2004-2011 ($ MILLIONS)
- RHEUMATOID ARTHRITIS AND RELATED INFLAMMATORY DISEASES
- THE MARKET FOR ENZYME INHIBITING DRUGS TO TREAT RHEUMATOID ARTHRITIS
AND RELATED
- Table 44 GLOBAL MARKET FORECAST FOR ENZYME-INHIBITING DRUGS TO TREAT
RHEUMATOID ARTHRITIS AND RELATED INFLAMMATORY DISEASES, THROUGH 2011 ($
MILLIONS)
- COMPANY PROFILES
- ABBOTT LABORATORIES
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- PRODUCTS
- CORPORATE STRATEGY
- ACHILLION PHARMACEUTICALS, INC.
- BUSINESS OVERVIEW
- PRODUCTS
- CORPORATE STRATEGY
- ALTANA PHARMA
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- PRODUCTS
- CORPORATE STRATEGY
- Corporate Strategy (Continued)
- BRISTOL-MYERS SQUIBB
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- PRODUCTS
- CORPORATE STRATEGY
- CELGENE CORPORATION
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- PRODUCTS
- FINANCIAL INFORMATION
- CORPORATE STRATEGY
- GILEAD SCIENCES INC.
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- PRODUCTS
- Table 45 GILEAD'S PRODUCT PIPELINE
- CORPORATE STRATEGY
- Corporate Strategy (Continued)
- GLAXOSMITHKLINE PLC
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- PRODUCTS
- Table 46 GLAXOSMITHKLINE'S ENZYME INHIBITOR PRODUCT PIPELINE
- ICOS CORPORATION
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- PRODUCTS
- CORPORATE STRATEGY
- IDENIX PHARMACEUTICALS, INC.
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- PRODUCTS
- CORPORATE STRATEGY
- INCYTE CORPORATION
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- PRODUCTS
- Table 47 INCYTE'S PRODUCT PIPELINE
- CORPORATE STRAGEGY
- Corporate Stragegy (Continued)
- MEDIVIR AB
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- PRODUCTS
- Table 48 MEDIVIR'S PRODUCT PIPELINE
- NOVARTIS AG
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- PRODUCTS
- CORPORATE STRATEGY
- PFIZER CORPORATION
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- PRODUCTS
- CORPORATE STRATEGY
- PHARMASSET, INC.
- BUSINESS OVERVIEW
- PRODUCTS
- CORPORATE STRATEGY
- PLEXXIKON, INC.
- BUSINESS OVERVIEW
- PRODUCTS
- CORPORATE STRATEGY
- SANTARUS, INC.
- BUSINESS OVERVIEW
- PRODUCTS
- CORPORATE STRATEGY
- TIBOTEC PHARMACEUTICALS LTD.
- BUSINESS OVERVIEW
- PRODUCTS
- CORPORATE STRATEGY
- VALEANT PHARMACEUTICALS INTERNATIONAL
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- PRODUCTS
- CORPORATE STRATEGY
- LIST OF TABLES
- Summary Table:
- GLOBAL FORECAST OF ENZYME INHIBITOR CLASS REVENUES, THROUGH 2011 ($
MILLIONS)
- Table 1 ENZYME INHIBITORS BY CLASS: DEFINITION AND EXAMPLES
- Table 2 GLOBAL MARKET FORECAST FOR COX-2 INHIBITORS BY PRODUCT THROUGH
2011 ($ MILLIONS)
- Table 3 U.S. MARKET FORECAST FOR COX-2 INHIBITORS BY PRODUCT THROUGH
2011 ($ MILLIONS)
- Table 4 GLOBAL MARKET FORECAST FOR PDE4 INHIBITORS BY PRODUCT, THROUGH
2011 ($ MILLIONS)
- Table 5 U.S. MARKET FORECAST FOR PDE4 INHIBITORS BY PRODUCT, THROUGH
2011 ($ MILLIONS)
- Table 6 PDE4 INHIBITORS IN PHASE II OR LATER DEVELOPMENT
- Table 7 GLOBAL MARKET FORECAST FOR PDE5 INHIBITORS BY PRODUCT, THROUGH
2011 ($ MILLIONS)
- Table 8 U.S. MARKET FORECAST FOR PDE5 INHIBITORS BY PRODUCT, THROUGH
2011 ($ MILLIONS)
- Table 9 PDE5 INHIBITORS IN PHASE II OR LATER DEVELOPMENT
- Table 10 BRANDED PRESCRIPTION PROTON PUMP INHIBITORS AND SUPPLIERS
- Table 11 GLOBAL MARKET FORECAST FOR PRESCRIPTION, BRANDED PROTON PUMP
INHIBITORS BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 12 U.S. MARKET FOR PRESCRIPTION, BRANDED PROTON PUMP INHIBITORS BY
PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 13 NUMBER OF DEATHS FROM AIDS IN THE U.S., 1988-2005
- Table 14 RESISTANCE AMONG HIV-POSITIVE PATIENTS IN EUROPE AS DETERMINED
BY THE CATCH STUDY
- Table 15 PROTEASE MUTATIONS
- Table 16 REVERSE TRANSCRIPTASE MUTATIONS
- Table 17 ADVANTAGES AND DISADVANTAGES OF GENOTYPIC VERSUS PHENOTYPIC
TESTING
- Table 18 ESTIMATED ANNUAL COSTS FOR HAART IN U.S. AND SUB-SAHARAN AFRICA
- Table 19 COMPARISON OF AVERAGE ANNUAL COST OF BOOSTED* PROTEASE
INHIBITOR-BASED HIV TREATMENT REGIMENS BEFORE AND AFTER NORVIR PRICE INCREASE
- Table 20 FDA-APPROVED DRUGS FOR THE TREATMENT OF HIV INFECTION/AIDS
- Table 21 GLOBAL MARKET FORECAST FOR ENZYME-INHIBITING HIV/AIDS
THERAPEUTICS, THROUGH 2011 ($ MILLIONS)
- Table 22 GLOBAL MARKET FORECAST FOR ENZYME-INHIBITING HIV/AIDS
THERAPEUTICS BY PRODUCT, THROUGH 2011 ($ MILLIONS)
- Table 23 U.S. MARKET FORECAST FOR ENZYME-INHIBITING HIV/AIDS
THERAPEUTICS, THROUGH 2011 ($ MILLIONS)
- Table 24 ENZYME INHIBITING PRODUCT INTRODUCTIONS FOR THE TREATMENT OF
HIV INFECTION, U.S.: 2002-2005
- Table 25 DAILY DOSAGE REQUIREMENTS FOR SELECTED HIV/AIDS THERAPIES
- Table 26 RELATIONSHIP BETWEEN COMPLIANCE AND DOSING FREQUENCY
- Table 27 ENZYME-INHIBITING PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR
THE TREATMENT AND/OR PREVENTION OF HIV INFECTION/AIDS
- Table 28 MARKETED NUCLEOSIDE ANALOG INHIBITORS FOR THE TREATMENT OF
OTHER VIRAL DISEASES
- Table 29 GLOBAL MARKET FORECAST FOR NUCLEOSIDE ANALOG-BASED DRUGS TO
TREAT OTHER VIRAL DISEASES, THROUGH 2011 ($ MILLIONS)
- Table 30 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
ASTHMA AND COPD, THROUGH 2011 ($ MILLIONS)
- Table 31 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
CARDIOVASCULAR DISEASES, THROUGH 2011 ($ MILLIONS)
- Table 32 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
ERECTILE DYSFUNCTION, THROUGH 2011 ($ MILLIONS)
- Table 33 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
GASTROINTESTINAL DISORDERS, THROUGH 2011 ($ MILLIONS)
- Table 34 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
HEPATITIS B INFECTION, THROUGH 2011 ($ MILLIONS)
- Table 35 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
HEPATITIS C INFECTION, THROUGH 2011
- Table 36 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
HERPESVIRUS INFECTIONS, THROUGH 2011 ($ MILLIONS)
- Table 37 ESTIMATED NUMBER OF PERSONS INFECTED WITH HIV/LIVING WITH AIDS,
ADULTS AND CHILDREN, BY GEOGRAPHIC REGION, 2005
- Table 38 PERCENTAGE OF GLOBAL HIV CASES BY GEOGRAPHIC REGION, 2005
- Table 39 ESTIMATED NUMBER OF PEOPLE NEWLY INFECTED WITH HIV, ADULTS AND
CHILDREN, BY GEOGRAPHIC REGION, 2005
- Table 40 ESTIMATED NUMBER OF DEATHS FROM AIDS, ADULTS AND CHILDREN, BY
GEOGRAPHIC REGION, 2005
- Table 41 ESTIMATED NUMBER OF PEOPLE INFECTED WITH HIV IN SELECTED
COUNTRIES, 2002 AND 2010 (MILLION)
- Table 42 PERCENT OF PATIENTS RECEIVING ANTIRETROVIRAL TREATMENT FOR HIV
INFECTION BY GEOGRAPHIC REGION
- Table 43 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT HIV
INFECTION AND AIDS, THROUGH 2011 ($ MILLIONS)
- Table 44 GLOBAL MARKET FORECAST FOR ENZYME-INHIBITING DRUGS TO TREAT
RHEUMATOID ARTHRITIS AND RELATED INFLAMMATORY DISEASES, THROUGH 2011 ($
MILLIONS)
- Table 45 GILEAD'S PRODUCT PIPELINE
- Table 46 GLAXOSMITHKLINE'S ENZYME INHIBITOR PRODUCT PIPELINE
- Table 47 INCYTE'S PRODUCT PIPELINE
- Table 48 MEDIVIR'S PRODUCT PIPELINE
- LIST OF FIGURES
- Summary Figure:
- PERCENTAGE OF REVENUES BY ENZYME INHIBITOR CLASS, IN 2005 AND 2011 (%)
- Figure 1 HOW AN ENZYME COMBINES TWO CHEMICALS
- Figure 2 COMPETITIVE INHIBITION
- Figure 3 NONCOMPETITIVE INHIBITION
- Figure 4 MARKET SHARE OF ENZYME-INHIBITING HIV/AIDS DRUGS BY PRODUCT
CATEGORY, WORLDWIDE SALES: 2006 AND 2011 ($ MILLIONS)
- Figure 5 U.S. MARKET FORECAST FOR ENZYME-INHIBITING HIV/AIDS
THERAPEUTICS, 2004-2011 ($ MILLIONS)
- Figure 6 GLOBAL MARKET FORECAST FOR NUCLEOSIDE ANALOG-BASED DRUGS TO
TREAT OTHER VIRAL DISEASES, 2004-2011 ($ MILLIONS)
- Figure 7 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
ASTHMA AND COPD, 2004-2011 ($ MILLIONS)
- Figure 8 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
CARDIOVASCULAR DISEASES, 2004-2011 ($ MILLIONS)
- Figure 9 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
ERECTILE DYSFUNCTION, 2004-2011 ($ MILLIONS)
- Figure 10 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
GASTROINTESTINAL DISORDERS, 2004-2011 ($ MILLIONS)
- Figure 11 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
HEPATITIS B INFECTION, 2004-2011 ($ MILLIONS)
- Figure 12 GLOBAL MARKET FORECAST FOR ENZYME INHIBITING DRUGS TO TREAT
HIV INFECTION AND AIDS, 2004-2011 ($ MILLIONS)
|
 |
